



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/592500/2013

## European Medicines Agency decision

P/0246/2013

of 4 October 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for exon 45 specific phosphorothioate oligonucleotide (EMEA-001369-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0246/2013

of 4 October 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for exon 45 specific phosphorothioate oligonucleotide (EMEA-001369-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Prosensa Therapeutics B.V. on 7 December 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 September 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for exon 45 specific phosphorothioate oligonucleotide, solution for injection / infusion, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for exon 45 specific phosphorothioate oligonucleotide, solution for injection / infusion, subcutaneous use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to Prosensa Therapeutics B.V., J.H. Oortweg 21, J.H. Oortweg 21, 2333 CH – Leiden, The Netherlands.

Done at London, 4 October 2013

For the European Medicines Agency  
Guido Rasi  
Executive Director  
(Signature on file)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/391207/2013

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-001369-PIP01-12

### Scope of the application

**Active substance(s):**

Exon 45 specific phosphorothioate oligonucleotide

**Condition(s):**

Treatment of Duchenne muscular dystrophy

**Pharmaceutical form(s):**

Solution for injection / infusion

**Route(s) of administration:**

Subcutaneous use

Intravenous use

**Name/corporate name of the PIP applicant:**

Prosensa Therapeutics B.V.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Prosensa Therapeutics B.V. submitted for agreement to the European Medicines Agency on 7 December 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 16 January 2013.

Supplementary information was provided by the applicant on 24 June 2013. The applicant proposed modifications to the paediatric investigation plan and withdrew its request for a waiver.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 13 September 2013

On behalf of the Paediatric Committee  
Dr Dirk Mentzer, Chairman  
(Signature on file)

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan**

## 1. Waiver

Not applicable.

## 2. Paediatric Investigation Plan

### 2.1. Condition: treatment of Duchenne muscular dystrophy

#### 2.1.1. Indication(s) targeted by the PIP

Treatment of patients with DMD bearing mutations that can be corrected by skipping exon 45.

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

#### 2.1.3. Pharmaceutical form(s)

Solution for injection / infusion.

#### 2.1.4. Measures

Area	Number of measures	Description
Quality	1	<b>Measure 1:</b> Development of a lower strength formulation.
Non-clinical	2	<b>Measure 2:</b> Intravenous (IV) bridging toxicity study <b>Measure 3:</b> IV and SC pharmacokinetic and tissue distribution study
Clinical	3	<b>Measure 4:</b> Open-label, multi-centre, dose escalating study followed by a 48 week treatment to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of Exon 45 specific phosphorothioate oligonucleotide (PRO045) in children from 3 years to less than 18 years of age with Duchenne Muscular Dystrophy (DMD) <b>Measure 5:</b> A Prospective Natural History Study of the Progression of Physical Impairment, Activity Limitation and Quality of Life in children Duchenne Muscular Dystrophy (DMD). <b>Measure 6:</b> Open-label, dose escalating trial to evaluate, pharmacokinetics, safety, activity, of multiple subcutaneous doses of Exon 45 specific phosphorothioate oligonucleotide (PRO045) in subjects with Duchenne muscular dystrophy (DMD) from birth to below 5 years of age in the presence or absence of corticosteroid therapy.

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2019
Deferral for one or more measures contained in the paediatric investigation plan:	Yes